Cempra sags after reporting Solithera setbacks

By Jaime De Leon | Feb 28, 2017 | 11:34 PM GMT

Cempra Inc. (NASDAQ:CEMP) lost $0.80 (19%) to $3.40 after reporting a pair of setbacks for antibiotic candidate Solithera solithromycin. The company said the candidate failed to show non-inferiority to standard of care (SOC) in the Phase III

Read the full 378 word article

How to gain access

Continue reading with a
two-week free trial.